Article 900 patients with asymptomatic diabetes mellitus were randomized to CT angiography vs. Standard management. Primary end point was a combination of death, infarction and unstable angina. 63% of patients randomized to CT angiography presented some degree of heart disease and 4.7% presented severe lesions. This resulted in more coronary interventions, more use of statins...

The treatment of hyperlipidemia is useful in primary and secondary prevention of chronic heart disease and stroke, particularly in diabetic patients. Many statins may interfere with glycemic profile of patients and there is no information between different drugs for some specific populations. 1049 patients randomized to rosuvastatin (n = 524) versus atorvastatin (n = 504)...

Daraplabid is a selective oral inhibitor of lipoprotein-associated phospholipase (Lp -PLA2)which is a potential agent for reducing cardiovascular events in patients with chronic ischemic heart disease.Lp-PLA2 is an enzyme found in the blood andatherosclerotic plaques and high levels are associated with an increased risk of cardiovascular events.Direct inhibition of this enzyme with proinflammatory Daraplabid may...

ROMA II RELOAD multicenter study (General Hospital Umberto I, University of Rome, Rome, Italy) assessed the impact of an additional charge of statin in patients undergoing elective angioplasty. All patients received a rosuvastatin dose of 40 mg (GR) or atorvastatin 80 mg (GA) within 24 hours of the procedure. The primary endpoint of the study...

Statins are the most effective treatment to reduce LDL levels and cardiovascular risk, 10-20% of patients are statin intolerant or present adverse effects at high doses (especially muscle damage). Ezetimibe is the alternative drug, though not as effective to reduce LDL, mainly in high risk patients. PSCK9 protein participates in LDL recycling, monoclonal antibody O...

The aim of this study was to determine whether patients without ST-segment elevation acute coronary syndromes who were not taking statins previously, can receive high doses of rosuvastatin before coronary angiography or angioplasty and if this action could exert protection in renal function and reduce the incidence of contrast-induced nephropathy (CIN). This prospective study randomized...

The THRIVE study, (also known as HPS2-THRIVE), was a multicenter clinical trial designed to test the hypothesis that the increase in HDL, (using ER niacin/laropiprant), could prevent vascular events in a high risk population already receiving statin standard therapy. Between April 2007 and July 2010 a total of 25,673 randomized patients in China, the UK...